Show simple item record

Chemoradiotherapy in gallbladder cancer

Authordc.contributor.authorAretxabala, Xabier de 
Authordc.contributor.authorRoa, Iván es_CL
Authordc.contributor.authorBerríos Flores, Marcela Paz es_CL
Authordc.contributor.authorHepp, Juan es_CL
Authordc.contributor.authorGallardo, Jorge es_CL
Authordc.contributor.authorCórdova, Andrés es_CL
Authordc.contributor.authorRoa, Juan Carlos 
Authordc.contributor.authorLeón, Jorge 
Authordc.contributor.authorMaluenda, Fernando 
Cita de ítemdc.identifier.citationJOURNAL OF SURGICAL ONCOLOGY Volume: 93 Issue: 8 Pages: 699-704 Published: JUN 15 2006en
Abstractdc.description.abstractGallbladder cancer (GC) is considered a rare disease associated with a poor prognosis. Unfortunately, the low number of cases makes the performance of trials addressing the role of adjuvant, neoadjuvant, and/or palliative therapy difficult. For a long time, the majority of trials were 5-fluorouracil (5 FU)-based, and results were uniformly poor. Since the introduction of Gemcitabine, response rates of approximately 30% have been observed through the use of this drug and new approaches have been tested. In this sense, drugs such as Cisplatin and Capecitabine have been employed concurrently with gemicitabine and/or radiation. Since a recurrence pattern is both distant and local, chemoradiation seems a logical option to deal with the disease. However, at the present time, the lack of valid and scientific evidence means that most of the recommendations originate from trials dealing with other tumors, such as pancreas cancer and biliary tract cancer (BTC). The aforementioned treatment alternatives Warrant further evaluation focusing on GC.en
Publisherdc.publisherWILEY-LISS, DIV JOHN WILEY & SONS INCen
Títulodc.titleChemoradiotherapy in gallbladder canceren
Document typedc.typeArtículo de revistaen

Files in this item


This item appears in the following Collection(s)

Show simple item record